Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma

Inclusion Criteria: * Fibrolamellar hepatocellular carcinoma histopathologically proven * Inoperable/advanced (Tumor recurrence inoperable or metastatic with no surgical indication). * Available Tumor tissue for analysis(biopsy or surgical specimen) * Performance status WHO ≤ 2. * Adequate organ function : * Hematology (absolute neutrophil count equal or superior to 1,5 x 10\*9/l , platelet equal or superior to 100 x 10\*9/l), * clearance of creatinine \> 60 ml/min), * AST/ALT ≤ 5 N, PAL ≤ 5 N, total bilirubin ≤ 2N. Exclusion Criteria: * Hypersensitivity to sunitinib. * Contraindication to sunitinib, including uncontrolled hypertension, medical history of cerebrovascular accident, unstable cardiac pathology despite optimal medical therapy (myocardial infarction within the 6 months prior to study drug administration, severe/unstable angina ), active hemorrhagic syndrome or concomitant treatment with anticoagulants. * Any severe acute or chronic co-morbid that may compromise to comply with study participation : uncontrolled infection, symptomatic congestive heart failure, liver disturbance, chronic renal failure, active gastro-duodenal ulcer (nonexhaustive list) * Known brain metastases. * Diagnosis of any second malignancy within the last 3 years, except for basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri * Current treatment on another clinical trial. * Prior treatment with an investigational agent within 4 weeks * Patient on i.v bis…